Key result
The presence of late gadolinium enhancement on CMR in patients with biopsy-negative graft dysfunction had no significant impact on the primary composite outcome compared to those without LGE.
Why the study?
Does cardiac magnetic resonance (CMR) imaging improve diagnosis and prognostic stratification in patients with biopsy-negative graft dysfunction post-heart transplantation?
Does cardiac magnetic resonance (CMR) imaging improve diagnosis and prognostic stratification in patients with biopsy-negative graft dysfunction post-heart transplantation?
Answers are grounded in this paper and cite their sources.
This editorial highlights that while cardiac magnetic resonance (CMR) shows promise as a complementary tool to characterize myocardial inflammation and fibrosis in biopsy-negative graft dysfunction after heart transplantation, treatment decisions should not rely solely on late gadolinium enhancement findings since they are absent in over half of cases and did not predict clinical outcomes.
Cardiac magnetic resonance (CMR) is widely used in diagnosing cardiomyopathies, heart failure of unknown aetiology, and ischaemic heart diseases.1, 2 In recent years, CMR has become a valuable tool for determining the underlying cause in acute conditions such as myocardial infarction with non-obstructive arteries (MINOCA) and myocarditis.3-7 In most myocarditis cases, the diagnosis can be confirmed based on clinical history and evidence of myocardial inflammation on CMR. Using the original Lake Louise criteria from 2009, which were developed to standardize the diagnosis of myocarditis based on CMR images, this technique demonstrated good specificity and sensitivity for detecting myocardial oedema.8 In 2018, these criteria were revised to include a new CMR sequence featuring paramagnetic mapping.9 It is recommended to perform CMR within the first 10–14 days from symptoms onset to increase the chance of oedema visualization.10 Tissue inflammation can be visualized on CMR using T2-based images, such as Short Tau Inversion Recovery (STIR) or modern T2-mapping. Additionally, with new CMR sequences such as T1-mapping, extracellular volume calculation, and T2*-mapping, CMR can monitor disease progression and treatment response in patients with conditions like amyloidosis, Fabry disease, or haemochromatosis.11 Recent studies have investigated changes in CMR parameters in heart failure patients with iron deficiency undergoing iron supplementation.12 After heart transplantation, it is crucial to closely monitor patients for signs of early cellular and humoral rejection.13 The gold standard to monitor cellular rejection is the endomyocardial biopsy, which is a planned procedure and is performed about 12 times in the first year. Based on the current histopathologic findings, where bioptomes are assessed according to the 2005 International Society of Heart and Lung Transplantation (ISHLT) heart biopsy grading scale, the immunotherapy is adjusted for each patient.14 However, due to the invasiveness and potential complications of endomyocardial biopsy, there has been significant focus, especially during the COVID-19 pandemic, on finding alternative, non-invasive methods to assess rejection in post-transplant patients. It is not surprising that CMR was one of the first techniques considered, due to its unique tissue characterization capabilities and only few contraindication.15, 16 One of the most significant studies in this field was a single-centre randomized controlled trial by Anthony et al., which demonstrated that a CMR-based multiparametric mapping approach (combining T1- and T2-mapping) during the first year after orthotopic heart transplantation is highly reproducible and reliable for detecting acute cardiac allograft rejection, making it a feasible alternative to endomyocardial biopsy-based surveillance.17 A much more complex topic is biopsy-negative graft dysfunction (GD) after heart transplantation (HTx). The pathophysiology, appropriate diagnostic criteria, and optimal treatment for these patients remain poorly understood.18 The varying definitions of biopsy-negative GD lead to heterogeneous study populations. It is typically diagnosed when cardiac dysfunction is observed, defined by a decline in left ventricular ejection fraction (LVEF) to ≤45%, despite normal histological findings and no other causes of cardiac allograft damage. Importantly, it has been shown that patients with haemodynamic compromise and a low ISHLT score have worse outcomes than those with a high score (indicating cellular rejection). It is believed that humoral rejection, involving immunologic mechanisms other than lymphocytic infiltration, is the primary cause of biopsy-negative GD, occurring in 10 to 20% of heart-transplanted patients.18 In this context, Anand et al. report in the current issue of ESC Heart Failure on the use of CMR in diagnosis biopsy-negative GD in post–Htx patients.19 As Htx remains a crucial treatment option for patients with end-stage heart failure, the authors are to be commended for their efforts to use modern cardiac imaging to better understand the rare and complex complication of biopsy-negative GD. Researchers from the Mayo Clinic in the USA defined biopsy-negative GD as a decrease in LVEF by more than 5% and an LVEF below 50%, in the absence of biopsy-proven rejection or allograft vasculopathy. This definition was met by 34 Htx recipients who underwent CMR between 2007 and 2020. The presented retrospective study had three aims: (1) to examine CMR findings in heart transplant recipients with biopsy-negative GD, (2) to evaluate outcomes based on the presence of LGE in CMR, and (3) to identify potential missed rejection cases in endomyocardial biopsy using CMR. The primary composite outcome consisted of all-cause mortality, re-transplantation, or persistent LVEF <50%. Regarding the first study aim, the authors shown that almost half of patients had presence of late gadolinium enhancement (LGE), all of non-ischaemic pattern. Interestingly, patients with LGE experienced GD later (4 vs. 1 year after Htx) were more often symptomatic (88% vs. 56%) and had higher pulmonary capillary wedge pressure (19 ± 7 vs. 13 ± 3 mmHg, all P < 0.05) compared with those without any LGE. Importantly, those differences had no significant impact on patients outcomes, including the primary composite outcome and improvement of LVEF during the median follow up of 3.8 years. These findings highlight the complex pathophysiology of biopsy-negative GD, where inflammation accounts for about 50% of cases, while neurohormonal and immunomodulatory mechanisms are significant in the remaining patients. Another important takeaway is that treatment decisions should not rely solely on CMR findings, as LGE is absent in over half of patients with biopsy-negative GD. However, there are some issues to note regarding the study by Anand et al. The main limitation of the study is that no parametric mapping techniques were tested, as the patients were retrospectively recruited from quite a long time period that covered 13 years, starting in 2007. It would have been very valuable to assess T1- and T2-mapping in that population of patients with biopsy-negative GD, as multiparametric approaches are already very promising in acute cardiac allograft rejection.15, 17 Another limitation is the retrospective nature and small sample size due to the rare occurrence of biopsy-negative GD. Therefore, it would be beneficial to conduct similar studies prospectively with a multicentre design and to include CMR findings in prospective multinational registries for post-HTx patients. Finally, the definition of biopsy-negative GD, based on a mere 5% decrease in LVEF resulting in an LVEF below 50%, may be unreliable in borderline cases due to inter- and intraobserver variability in LVEF measurement. This variability could lead to inconsistent diagnoses and underscores the need for more precise criteria. In conclusion, CMR imaging is emerging as a valuable diagnostic tool for post-HTx patients who require close monitoring for signs of organ rejection. Its unique tissue characterization ability, non-invasive nature, and increasing availability make it a promising alternative. Growing evidence supports its effectiveness in detecting acute cellular rejection, offering a feasible option compared to the gold standard of endomyocardial biopsy. In the rare condition of biopsy-negative GD, CMR shows promise as a complementary diagnostic tool for better understanding underlying pathomechanisms. However, this field is still in its early stages and requires further exploration.
No takes yet. Share an insight, caveat, or question.
Sokolska et al. (2024) conducted an editorial in Biopsy-negative graft dysfunction post-heart transplantation (n=34). Presence of late gadolinium enhancement (LGE) on CMR vs. Absence of LGE on CMR was evaluated on Composite of all-cause mortality, re-transplantation, or persistent LVEF <50%. The presence of late gadolinium enhancement on CMR in patients with biopsy-negative graft dysfunction had no significant impact on the primary composite outcome compared to those without LGE.
Synapse has enriched 10 related papers. Consider them for comparative context: